Geode Capital Management
NNNN icon

Geode Capital Management’s Anbio Biotechnology NNNN Stock Holding History

Geode Capital Management’s Portfolio NNNN Stock Details NNNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$140K Sell
22,209
-4,527
-17% -$38.5K ﹤0.01% 3973
2026
Q2 		$367K Buy
26,736
+973
+4% +$24.4K ﹤0.01% 3711
2026
Q1 		$662K Hold
25,763
– – ﹤0.01% 3484
2025
Q4 		$775K Hold
25,763
– – ﹤0.01% 3452
2025
Q3 		$960K Buy
25,763
+8,633
+50% +$388K ﹤0.01% 3393
2025
Q2 		$542K Buy
17,130
+70
+0.4% +$670 ﹤0.01% 3531
2025
Q1 		$127K Buy
+17,060
New +$117K ﹤0.01% 3966

Other funds holding NNNN

Larson Financial Group
Larson Financial Group St Louis, Missouri $4.11B AUM 23.62% 1-Year Est. Return
EverSource Wealth Advisors
EverSource Wealth Advisors Birmingham, Alabama $3.11B AUM 21.48% 1-Year Est. Return
Pinnacle Wealth Planning Services
Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return

Geode Capital Management's NNNN Position: Q3 2026 in Review

Geode Capital Management reduced its Anbio Biotechnology (NNNN) stake by 17% in Q3 2026, selling an estimated $38.5K and leaving 22,209 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #3973.

Geode Capital Management first reported a position in NNNN in Q1 2025 and has held it in 7 quarters since. The position peaked at $960K in Q3 2025. 4 funds tracked by Wall St. Rank hold NNNN as of Q3 2026.

  • Geode Capital Management held 22,209 shares of Anbio Biotechnology worth $140K as of Q3 2026.
  • Geode Capital Management sold 4,527 Anbio Biotechnology shares in Q3 2026, an estimated $38.5K.
  • Anbio Biotechnology made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3973 holding.
  • Geode Capital Management first reported a position in Anbio Biotechnology in Q1 2025 and has held it in 7 quarters since.
  • Geode Capital Management's Anbio Biotechnology position peaked at $960K in Q3 2025.
  • 4 funds tracked by Wall St. Rank held Anbio Biotechnology as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.